Literature DB >> 15964073

Nicotine use in schizophrenia: the self medication hypotheses.

Veena Kumari1, Peggy Postma.   

Abstract

The behavioural and cognitive effects of nicotine in schizophrenia have received much interest in recent years. The rate of smoking in patients with schizophrenia is estimated to be two- to four-fold the rate seen in the general population. Furthermore such patients favour stronger cigarettes and may also extract more nicotine from their cigarettes than other smokers. The question has been raised whether the widespread smoking behaviour seen in this patient group is in fact a manifestation of a common underlying physiology, and that these patients smoke in an attempt to self-medicate. We present an overview of the explanations for elevated rates of smoking in schizophrenia, with particular emphasis on the theories relating this behaviour to sensory gating and cognitive deficits in this disorder that have been viewed as major support for the self-medication hypotheses.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15964073     DOI: 10.1016/j.neubiorev.2005.02.006

Source DB:  PubMed          Journal:  Neurosci Biobehav Rev        ISSN: 0149-7634            Impact factor:   8.989


  148 in total

1.  Transcriptional repression of the α7 nicotinic acetylcholine receptor subunit gene (CHRNA7) by activating protein-2α (AP-2α).

Authors:  Jessica Finlay-Schultz; Andrew Canastar; Margaret Short; Mohamed El Gazzar; Christina Coughlan; Sherry Leonard
Journal:  J Biol Chem       Date:  2011-10-06       Impact factor: 5.157

2.  Non-cholinergic modulation of antisaccade performance: a modafinil-nicotine comparison.

Authors:  N Rycroft; S B Hutton; O Clowry; C Groomsbridge; A Sierakowski; J M Rusted
Journal:  Psychopharmacology (Berl)       Date:  2007-08-05       Impact factor: 4.530

Review 3.  Neurotensin agonists: potential in the treatment of schizophrenia.

Authors:  Mona Boules; Amanda Shaw; Paul Fredrickson; Elliott Richelson
Journal:  CNS Drugs       Date:  2007       Impact factor: 5.749

Review 4.  Modulation of hippocampus-dependent learning and synaptic plasticity by nicotine.

Authors:  Justin W Kenney; Thomas J Gould
Journal:  Mol Neurobiol       Date:  2008-08-09       Impact factor: 5.590

Review 5.  CNTRICS final task selection: long-term memory.

Authors:  John D Ragland; Roshan Cools; Michael Frank; Diego A Pizzagalli; Alison Preston; Charan Ranganath; Anthony D Wagner
Journal:  Schizophr Bull       Date:  2008-10-16       Impact factor: 9.306

6.  Mesolimbic dopamine and habenulo-interpeduncular pathways in nicotine withdrawal.

Authors:  John A Dani; Mariella De Biasi
Journal:  Cold Spring Harb Perspect Med       Date:  2013-06-01       Impact factor: 6.915

7.  Nicotine restores Wt-like levels of reelin and GAD67 gene expression in brain of heterozygous reeler mice.

Authors:  Emilia Romano; Andrea Fuso; Giovanni Laviola
Journal:  Neurotox Res       Date:  2013-02-06       Impact factor: 3.911

8.  Lifetime cannabis use and cognition in patients with schizophrenia spectrum disorders and their unaffected siblings.

Authors:  Ana M Sánchez-Torres; Virginia Basterra; Araceli Rosa; Lourdes Fañanás; Amalia Zarzuela; Berta Ibáñez; Víctor Peralta; Manuel J Cuesta
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2013-04-12       Impact factor: 5.270

9.  Effects of COMT genotype on sensory gating and its modulation by nicotine: Differences in low and high P50 suppressors.

Authors:  S de la Salle; D Smith; J Choueiry; D Impey; T Philippe; H Dort; A Millar; P Albert; V Knott
Journal:  Neuroscience       Date:  2013-03-25       Impact factor: 3.590

Review 10.  Nicotine and nicotinic system in hypoglutamatergic models of schizophrenia.

Authors:  Yousef Tizabi
Journal:  Neurotox Res       Date:  2007-12       Impact factor: 3.911

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.